Lixte appoints Bas van der Baan as President and CEO; founder Kovach becomes Executive Chairman

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Bastiaan van der Baan named President, CEO and Vice Chairman effective September 26, 2023.
Founder John S. Kovach, M.D. becomes Executive Chairman, remains Chief Scientific Officer.
Employment agreement: 3-year term, $150,000 annual salary, with discretionary bonus.
Granted options to purchase 250,000 shares at $1.95, vesting quarterly over 3 years.
van der Baan brings 20+ years biotech experience; previously Chief Clinical Officer at Agendia.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

John S. Kovach

Executive Chairman

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2023-09-26
Filed: September 27, 2023, 7:59 PM ET

Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John S. Kovach was appointed as Executive Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Executive Chairman

Exact text from the filing

Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.

View on SEC.gov

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-033825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.